Research & Development

Research & Development

Nuclear Medicine

Presentation

The department of Nuclear Medicine of the Bordet Institute focusses exclusively on the diagnostic and therapeutic applications of radiolabeled molecules in clinical and experimental oncology.

The diagnostic information obtained by these techniques is mainly metabolic and is, by this, completely complementary to the structural information obtained with radiologic imaging techniques (such as ultrasound, CT and MRI).

It has recently been recognised that bringing together metabolic and structural information yields a better overall diagnosis and patient management in oncology. For this reason, modern PET (but also SPECT cameras) do have an integrated CT scan, allowing combined acquisition and image analysis.

Nuclear Medicine is essentially a multidisciplinary speciality requiring an intense collaboration between the nuclear medicine physician, the radiophysicist, the imaging ingenieer and technologist,and the radiopharmacist.

The Nuclear Medicine departement of the Bordet Institute consists of three major parts: conventional nuclear medicine (SPECT), positron emission tomography (PET), and the therapeutic applications.

The PET-CT unit is part of the Iris Brussels Public Hospital Network.

Logistically, the department harbours two SPECT and one PET-CT camera, performing about 6500 diagnostic examinations (4000 and 2500, respectively) and performs 85 therapeutic applications per year.

 

Conventional nuclear medicine : SPECT (click here)

- Sentinel Node Scintigraphy
- Multi Drug Resistance

 

Positron Emission Tomography (click here)

- Assesment of the efficacy of a treatment

- Somatostatin Receptor Imaging

- PET-CT based dosimetry for radio-imunotherapy

 

The therapeutic applications of radionuclides (click here)

- Yttrium-90 labelled microspheres

- Yttrium-90 labellled monoclonal antibodies against lymphoma

 

The TEAM members with their specific focus of R&D interest

• Nuclear Medicine Physician
  Prof. Patrick Flamen (Head of Nuclear Medicine)
  - PET-CT imaging in oncology
  - Therapy Monitoring using PET-CT
  - Yttrium-90 labeled microspheres for treatment of hepatic malignancies
  - Digestive Oncology
  - Head and Neck cancer
  - Neuro-endocrine tumors
  
  Prof. Pierre Bourgeois (Chief of Clinic of Nuclear Medicine)
  - Thyroid cancer: diagnostic and therapeutic aspects
  - Sentinel Node Scintigraphy
  - Multi Drug Resistance
  - Therapeutic Applications of Radionuclides
  - Lymphology
  - Radiobiological effects of radionuclides
  
  Dr. Kristoff Muylle (Resident in Nuclear medicine)
  - PET-CT imaging in oncology
  - Radioimunotherapy (anti CD-20)
  - Dosimetry (using PET-CT)
  - Lymphoma (PET-CT)
  
  Dr. Camillo Garcia (Resident in Nuclear Medicine)
  Starting october 2006
   
• Radiophysics and Ingenieering
  Bruno Vanderlinden
  - Dosimetry
  
  Thierry Gevaert
  - Imaging technology
   
• Radiopharmacy
  Prof. Ghanem Ghanem
  - Experimental Oncology